natalizumab (Tysabri)

07/01/2011 - "Post hoc analysis of phase III clinical trials and the results of post-approval observational studies indicate that natalizumab significantly increases the proportion of patients with complete clinical and radiological response and is effective in patients with highly active forms of multiple sclerosis and suboptimal response to other treatments. "
06/01/2014 - "MRI is the most powerful method in the detection of natalizumab-associated PML by showing imaging patterns helpful in the differentiation between PML and multiple sclerosis lesions. "
01/01/2013 - "Natalizumab inhibits the transmigration of activated T lymphocytes into the brain and is highly efficacious in multiple sclerosis (MS). "
10/29/2012 - "The discovery of natalizumab, a potent therapeutic for multiple sclerosis."
09/01/2009 - "Natalizumab is a monoclonal antibody targeted against alpha-4 integrin that has proved to be very effective in the treatment of multiple sclerosis. "

11/01/2015 - "Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System."
04/01/2014 - "Natalizumab is a highly effective treatment for patients with relapsing-remitting multiple sclerosis (RRMS). "
01/01/2014 - "Natalizumab is highly effective in relapsing-remitting multiple sclerosis and might be considered as an option. "
03/01/2013 - "Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. "
01/01/2013 - "Natalizumab is a highly effective treatment for relapsing-remitting multiple sclerosis (MS). "

01/01/2009 - "Natalizumab is already approved for clinical use and targets alpha4 with proven efficacy in Crohn's disease. "
01/02/2003 - "Natalizumab also produced a significant improvement in response rates (defined by a reduction of at least 70 points in the score on the Crohn's Disease Activity Index). "
01/02/2003 - "The group given two infusions of 6 mg of natalizumab per kilogram did not have a significantly higher rate of clinical remission (defined by a score of less than 150 on the Crohn's Disease Activity Index) than the placebo group at week 6 (the prospectively defined primary end point in the efficacy analysis). "
01/01/2007 - "Pooled data from the four included studies suggest that natalizumab (300 mg or 3 to 4 mg/kg) is effective for induction of clinical response and remission in patients with moderately to severely active Crohn's disease. "
01/01/2006 - "Pooled data and the results of an ongoing study suggest that natalizumab may be effective for induction of clinical response and remission in patients with moderately to severely active Crohn's disease. "

04/01/2011 - "Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. "
09/01/2010 - "Natalizumab is a therapy which, although associated with a 1 : 1000 risk for progressive multifocal leukoencephalopathy (PML), has been shown to be well tolerated in the adult population and may lead to disease remission in adults with highly active disease. "
01/01/2012 - "While having shown high therapeutic efficacy, treatment by natalizumab has been linked to progressive multifocal leukoencephalopathy (PML) as a serious adverse effect. "
03/01/2012 - "This review first analyzes the experience from the early stages of the disease-modifying therapies, then, expanding on the concept of early treatment for improved outcomes, it focuses on natalizumab and its major complication, progressive multifocal leukoencephalopathy. "
09/01/2012 - "Natalizumab, the first drug brought to market targeting CAMs, is clinically effective but is associated with serious adverse effects including the uncommon, but often fatal, neurological disease progressive multifocal leukoencephalopathy. "

01/01/2009 - "Natalizumab (NZ) has been shown to be effective in reducing relapses and disease progression. "
08/01/2005 - "After demonstrating the safety and potential effectiveness of natalizumab in MS therapy during shorter treatment periods (</=6 months) in clinical phase I and II studies, two ongoing large, double-blinded, placebo-controlled phase III trials (named AFFIRM and SENTINEL) are evaluating its efficacy for patients with relapsing-remitting MS in respect to primary clinical endpoints (relapse rate, disease progression). "
04/27/2010 - "The impact of natalizumab on HRQoL outcomes in patients with relapsing-remitting MS was evident at 2 years regardless of sustained disease progression or relapse status. "
06/01/2015 - "Natalizumab treatment has been shown to be very efficacious in clinical trials and very effective in clinical practice in patients with relapsing-remitting multiple sclerosis, by reducing relapses, slowing disease progression, and improving magnetic resonance imaging patterns. "
04/14/2007 - "Two large randomised clinical trials were published in March 2006 that evaluated the effect of natalizumab on the incidence of disease exacerbation in patients with multiple sclerosis (MS). "